Wed.Aug 03, 2022

Alnylam drug succeeds in key heart disease study, boosting company

Bio Pharma Dive

The success of Alnylam's treatment in a trial known as APOLLO-B could pave the way for the biotech to reach consistent profitability, should the FDA sign off on a planned approval application

Trials 285

Should you take a job with a biotech startup?

World of DTC Marketing

At first, the opportunity to join a small biotech startup sounds excellent. Smaller staff usually means less bureaucracy and being on the ground floor of a potentially financially rewarding career. But there are risks.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Roche digs into off-the-shelf cell therapy with Poseida deal

Bio Pharma Dive

The pharma has now signed two alliances with allogeneic drug developers since September, signalling its interest in CAR-T treatment alternatives

Drugs 272

It’s My Party and I’ll Cry if I Want to: A Bittersweet Happy 30th Birthday to LDTs

FDA Law Blog

By Jeffrey N. Gibbs & Allyson B. Mullen — Happy Birthday Laboratory Developed Tests (LDTs). Thirty years ago today, FDA announced that it had the authority to regulate you.

2022 Research: The Rapid Rise of Ocean Freight Visibility

Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.

AbCellera inks another venture partnership, this time with Atlas

Bio Pharma Dive

One week after striking a deal with Versant, the antibody specialist is teaming up with Atlas to provide drug candidates to an undisclosed startup backed by the biotech investor

Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again

Fierce Pharma

Merck's Keytruda, on a losing streak, fails in once FDA-rejected liver cancer use and prostate cancer—again. Wed, 08/03/2022 - 11:22

100
100

More Trending

Connecting EHR to clinical trials: How to embrace the promise of real-world data

pharmaphorum

We all know that real-world data (RWD) from electronic health records (EHR) could boost clinical trial efficiency and improve patient outcomes – so what’s holding us back?

Coherus wins FDA approval for second Lucentis biosimilar, its third drug

Bio Pharma Dive

The biotech company secured a valuable interchangeable designation for the copycat medicine, which it plans to launch later this year

Gilead Sciences’ push into oncology is paying off, as Veklury falters

pharmaphorum

Gilead Sciences’ investment in oncology has started to provide a solid return, with sales of cancer therapies breaching the $500 million threshold for the first time in the second quarter.

In GSK trade secrets case, appeals court backs short sentences against prosecutors' wishes

Fierce Pharma

In GSK trade secrets case, appeals court backs short sentences against prosecutors' wishes. zbecker. Wed, 08/03/2022 - 15:15

87

An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space

Speaker: Steve Goldstein, Sales Leader

Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.

Roche adds to pipeline with Poseida, Kiniksa deals

pharmaphorum

Roche has announced a pair of licensing deals with Poseida Therapeutics and Kiniksa Pharmaceuticals that bolster its pipeline in cancer and inflammatory diseases.

After forking over $900M for Libtayo rights, Regeneron expects slight delay for lung cancer combo

Fierce Pharma

After forking over $900M for Libtayo rights, Regeneron expects slight delay for lung cancer combo. fkansteiner. Wed, 08/03/2022 - 12:37

87

Rigel and Forma enter licence deal for acute myeloid leukaemia therapy

Pharmaceutical Technology

Rigel Pharmaceuticals has signed a licence agreement with Forma Therapeutics for developing, producing and marketing olutasidenib to potentially treat relapsed/refractory acute myeloid leukaemia (R/R AML) and other types of cancer. .

Sales 56

Coherus, after FDA approval for interchangeable Lucentis biosim, plots October launch

Fierce Pharma

Coherus, after FDA approval for interchangeable Lucentis biosim, plots October launch. fkansteiner. Wed, 08/03/2022 - 08:11

Mandatory COVID Vaccination Policy Template

The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.

Quantro and Boehringer Ingelheim collaborate on inhibitors

PharmaTimes

Deal represents part of Boehringer Ingelheim’s strategy to provide breakthrough cancer therapies

76

Negotiations? AbbVie CEO says current Senate proposal brings 'price controls' instead

Fierce Pharma

Negotiations? AbbVie CEO says current Senate proposal brings 'price controls' instead. esagonowsky. Wed, 08/03/2022 - 07:57

87

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

The Pharma Data

Growing late-stage research pipeline, addressing areas of high unmet medical need Pipeline includes areas such as rare skin disease, pulmonary fibrosis, oncology and central nervous system disease Net sales rise currency-adjusted by 9.5 percent to 11.2 billion EUR.

Eying Pfizer, Alnylam's high-stakes Onpattro heart trial delivers partial win but misses on key outcomes goal

Fierce Pharma

Eying Pfizer, Alnylam's high-stakes Onpattro heart trial delivers partial win but misses on key outcomes goal. Wed, 08/03/2022 - 09:40

Roche’s subcutaneous formulation of Tecentriq demonstrates positive Phase III results

The Pharma Data

Gilead reports 1% rise in revenue for Q2 2022

Pharmaceutical Technology

Gilead Sciences has reported a 1% growth in revenue to $6.3bn in the second quarter (Q2) of 2022 as against $6.2bn in the year-ago quarter.

Sales 52

Bayer Consumer Health leaders propose new principles for science-led self-care

The Pharma Data

Empowering consumers to take more control over their own health means ensuring they have the knowledge and trust that products are safe and will work as described / The Principles of Science-Led Self-Care paper forms a blueprint for the industry.

Solving pharma’s process development challenges one API at a time

Pharmaceutical Technology

The discovery of a new chemical entity (NCE) that could potentially lead the way to a ground-breaking therapeutic treatment is an exciting prospect for any chemist.

June Air Freight Stats Support Resiliency, IATA Says

Pharmaceutical Commerce

Association’s director general recommends air cargo developments be closely monitored in second half of year.

Internet of things hiring levels in the pharmaceutical industry rose in July 2022

Pharmaceutical Technology

The proportion of pharmaceutical companies hiring for internet of things related positions rose in July 2022 compared with the equivalent month last year, with 18.2% of the companies included in our analysis recruiting for at least one such position. This latest figure was higher than the 14.6%

52

Mobilizing against monkeypox

Elsevier

As the world continues to navigate Covid and its many strains, it would be an understatement to say that everyone is on high alert for other types of outbreaks.

New life sciences development destined for Paddington

PharmaTimes

The sites will maximise local and global benefits of NHS, research, industry and community partnerships

Oregon Freeze Dry Opens $7.5 Million Biopharma Facility

Pharmaceutical Commerce

New facility will provide lyophilization services.

40

HERBAL / NATURAL INGREDIENTS FOR SKIN NOURISHMENT FROM A TO Z

Pharmatutor

HERBAL / NATURAL INGREDIENTS FOR SKIN NOURISHMENT FROM A TO Z. About Authors. Avdesh Thassu. MPharm (Nat. Chem.); MBA(Mkt.). admin. Wed, 08/03/2022 - 15:44. Articles. Read more about HERBAL / NATURAL INGREDIENTS FOR SKIN NOURISHMENT FROM A TO Z Log in or register to post comments

56

Pressure rises on Lucentis, as Coherus biosimilar gets FDA nod

pharmaphorum

The US FDA has approved a new biosimilar of Roche and Novartis’ blockbuster ophthalmology therapy Lucentis – Coherus BioSciences’ Cimerli – which its developer claims is the first to be fully interchangeable with the originator product.

New patent for Cmp Dev drug CAROSPIR

Drug Patent Watch

Annual Drug Patent Expirations for CAROSPIR Carospir is a drug marketed by Cmp Dev Llc and is included in one NDA. It is available from two suppliers. There are five…. The post New patent for Cmp Dev drug CAROSPIR appeared first on DrugPatentWatch - Make Better Decisions. Patent Added

Chinese biotech Sironax raises $200m for RIPK1 pipeline

pharmaphorum

Beijing biotech Sironax has closed a whopping $200 million second-round financing that shows investors still have a desire to back companies working on RIPK1 inhibitors despite setbacks for GSK in the class.

New patent for Gilead Sciences drug VEKLURY

Drug Patent Watch

Annual Drug Patent Expirations for VEKLURY Veklury is a drug marketed by Gilead Sciences Inc and is included in one NDA. It is available from one supplier. There are ten…. The post New patent for Gilead Sciences drug VEKLURY appeared first on DrugPatentWatch - Make Better Decisions. Patent Added

Phase 3 lung cancer fail dents prospects of Ipsen, Servier’s Onivyde

pharmaphorum

Ipsen and Servier’s hopes of extending the uses for chemotherapy drug Onivyde have been knocked back by a failed phase 3 trial of the drug as a second-line therapy for small cell lung cancer (SCLC).

EVERSANA INTOUCH Recognized as a Finalist for Multiple SEO Industry Awards 

Intouch Solutions

The U.S. Search Awards have been recognizing the best and brightest in search marketing for over a decade, and that recognition is coming to EVERSANA INTOUCH’s SEO team.